Insight change and its relationship to subjective well-being during acute atypical antipsychotic treatment in schizophrenia

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 6, 2011, Pages 687-694

  Kim, Jong Hoon ^a   Ann, Jun Hyung ^a   Lee, Jinyoung ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

atypical antipsychotics; insight; schizophrenia

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; AWARENESS; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; DEPRESSION; DISEASE DURATION; EDUCATIONAL STATUS; FEMALE; HUMAN; MALE; PATIENT ATTITUDE; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOLOGICAL WELL BEING; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SELF CONCEPT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; YOUNG ADULT;

EID: 80055039630     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01230.x     Document Type: Article

References (58)

1. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM, (1993) Assessment of insight in psychosis. American Journal of Psychiatry, 150, 873-879. (Pubitemid 23156765)
2. Amador XF, Flaum M, Andreasen NC, Strauss DH, Yale SA, Clark SC, Gorman JM, (1994) Awareness of illness in schizophrenia and schizoaffective and mood disorders. Archives of General Psychiatry, 51, 826-836. (Pubitemid 24313308)
3. Buckley PF, Wirshing DA, Bhushan P, Pierre JM, Resnick SA, Wirshing WC, (2007) Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs, 21, 129-141.
4. Mintz AR, Dobson KS, Romney DM, (2003) Insight in schizophrenia: a meta-analysis. Schizophrenia Research, 61, 75-88. (Pubitemid 36332142)
5. Pini S, Cassano GB, Dell'Osso L, Amador XF, (2001) Insight into illness in schizophrenia, schizoaffective disorder, and mood disorders with psychotic features. American Journal of Psychiatry, 158, 122-125. (Pubitemid 32047257)
6. Goldberg RW, Green-Paden LD, Lehman AF, Gold JM, (2001) Correlates of insight in serious mental illness. Journal of Nervous and Mental Disease, 189, 137-145. (Pubitemid 32220995)
7. Karow A, Pajonk FG, (2006) Insight and quality of life in schizophrenia: recent findings and treatment implications. Current Opinion of Psychiatry, 19, 637-641. (Pubitemid 44520381)
8. David A, Buchanan A, Reed A, Almeida O, (1992) The assessment of insight in psychosis. British Journal of Psychiatry, 161, 599-602.
9. Kemp RA, Lambert TJ, (1995) Insight in schizophrenia and its relationship to psychopathology. Schizophrenia Research, 18, 21-28.
10. Moore O, Cassidy E, Carr A, Callaghan EO, (1999) Unawareness of illness and its relationship with depression and selfdeception in schizophrenia. European Psychiatry, 14, 264-269. (Pubitemid 36187785)
11. Sevy S, Nathanson K, Visweswaraiah H, Amador X, (2004) The relationship between insight and symptoms in schizophrenia. Comprehensive Psychiatry, 45, 16-19. (Pubitemid 38029970)
12. Gharabawi GM, Lasser RA, Bossie CA, Zhu Y, Amador X, (2006) Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. International Clinical Psychopharmacology, 21, 233-240. (Pubitemid 43740301)
13. Gharabawi G, Bossie C, Turkoz I, Kujawa M, Mahmoud R, Simpson G, (2007) The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. Journal of Nervous and Mental Disease, 195, 976-982. (Pubitemid 350306550)
14. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B, (2001) Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophrenia Research, 50, 79-88. (Pubitemid 32510889)
15. Karow A, Naber D, (2002) Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology, 162, 3-10. (Pubitemid 34639549)
16. Awad AG, Voruganti LN, (2004) Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs, 18, 877-893. (Pubitemid 39612017)
17. Browne S, Garavan J, Gervin M, Roe M, Larkin C, O'Callaghan E, (1998) Quality of life in schizophrenia: insight and subjective response to neuroleptics. Journal of Nervous and Mental Disease, 186, 74-78. (Pubitemid 28117637)
18. Williams CC, Collins A, (2002) Factors associated with insight among outpatients with serious mental illness. Psychiatric Services, 53, 96-98. (Pubitemid 34038624)
19. Hofer A, Rettenbacher MA, Widschwendter CG, Kemmler G, Hummer M, Fleischhacker WW, (2006) Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. European Archives of Psychiatry and Clinical Neuroscience, 256, 246-255. (Pubitemid 43989509)
20. Lysaker PH, Bell MD, Bryson GJ, Kaplan E, (1998) Insight and interpersonal function in schizophrenia. Journal of Nervous and Mental Disease, 186, 432-436. (Pubitemid 28363360)
21. Vaz FJ, Bejar A, Casado M, (2002) Insight, psychopathology, and interpersonal relationships in schizophrenia. Schizophrenia Bulletin, 28, 311-317. (Pubitemid 35462246)
22. Ritsner M, (2003) Predicting changes in domain-specific quality of life of schizophrenia patients. Journal of Nervous and Mental Disease, 191, 287-294. (Pubitemid 36627202)
23. Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA, (2009) Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin, 35, 336-346.
24. Hasson-Ohayon I, Kravetz S, Roe D, David AS, Weiser M, (2006) Insight into psychosis and quality of life. Comprehensive Psychiatry, 47, 265-269. (Pubitemid 43870062)
25. Karow A, Pajonk FG, Reimer J, Hirdes F, Osterwald C, Naber D, Moritz S, (2008) The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life. European Archives of Psychiatry and Clinical Neuroscience, 258, 152-159. (Pubitemid 351642152)
26. Schwartz RC, Smith SD, (2004) Suicidality and psychosis: the predictive potential of symptomatology and insight into illness. Journal of Psychiatric Research, 38, 185-191. (Pubitemid 38134460)
27. Sim K, Mahendran R, Siris SG, Heckers S, Chong SA, (2004) Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Research, 129, 141-147. (Pubitemid 39601810)
28. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn (DSM-IV). Washington DC: American Psychiatric Association.
29. Naber D, Riedel M, Klimke A, et al. (2005) Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatrica Scandinavica, 111, 106-115. (Pubitemid 40293177)
30. Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, Czekalla J, (2006) Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. Journal of Clinical Psychiatry, 67, 1690-1697. (Pubitemid 44955148)
31. de Haan L, Weisfelt M, Dingemans PM, Linszen DH, Wouters L, (2002) Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology, 162, 24-28. (Pubitemid 34639552)
32. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D, (2003) Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. American Journal of Psychiatry, 160, 303-309. (Pubitemid 41110456)
33. Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W, (2007) Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophrenia Research, 91, 178-186.
34. Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W, Schimmelmann BG, Lambert M, (2008) Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Journal of Psychiatric Research, 42, 676-683. (Pubitemid 351635797)
35. Karow A, Moritz S, Lambert M, Schoder S, Krausz M, (2005) PANSS syndromes and quality of life in schizophrenia. Psychopathology, 38, 320-326. (Pubitemid 43074271)
36. Yoon JS, Kook SH, Lee HY, Lee C, Paik IH, (2000) The development of a Korean modification of the scale to measure Subjective Well-being under Neuroleptic Treatment (SWN). Journal of Korean Neuropsychiatric Association, 39, 987-998.
37. Kay SR, Fiszbein A, Opler LA, (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276. (Pubitemid 18039085)
38. Beck AT, Ward CH, Mendelson M, Mock J, Erbauch J, (1961) An inventory for measuring depression. Archives of General Psychiatry, 4, 561-571.
39. Bell MD, Lysaker PH, Beam-Goulet JL, Milstein RM, Lindenmayer JP, (1994) Five-component model of schizophrenia: assessing the factorial invariance of the positive and negative syndrome scale. Psychiatry Research, 52, 295-303. (Pubitemid 24225427)
40. Whitehorn D, Brown J, Richard J, Rui Q, Kopala L, (2002) Multiple dimensions of recovery in early psychosis. International Review of Psychiatry, 14, 273-283. (Pubitemid 35398853)
41. Hwang SS, Chang JS, Lee KY, Kim SH, Ahn YM, Kim YS, (2009) Causal model of insight and psychopathology based on the PANSS factors: 1-year cross-sectional and longitudinal revalidation. International Clinical Psychopharmacology, 24, 189-198.
42. Stefanopoulou E, Lafuente AR, Saez Fonseca JA, Huxley A, (2009) Insight, global functioning and psychopathology amongst in-patient clients with schizophrenia. Psychiatric Quarterly, 80, 155-165.
43. Inada T, Yagi G, Miura S, (2002) Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophrenia Research, 57, 227-238. (Pubitemid 35240025)
44. Kim JH, Jung HY, Kang UG, et al. (2002) Metric characteristics of the DIEPSS: a practical combined rating scale for drug-induced movement disorders. Movement Disorders, 17, 1354-1359. (Pubitemid 36041355)
45. Kim JH, Cho SY, Byun HJ, Kang UG, Ahn YM, Kim YS, (2004) Multidimensional sensory phenomena in antipsychotic-induced akathisia. Journal of Clinical Psychopharmacology, 24, 618-623. (Pubitemid 39518657)
46. Keshavan MS, Rabinowitz J, DeSmedt G, Harvey PD, Schooler N, (2004) Correlates of insight in first episode psychosis. Schizophrenia Research, 70, 187-194. (Pubitemid 39141097)
47. Drake RJ, Pickles A, Bentall RP, Kinderman P, Haddock G, Tarrier N, Lewis SW, (2004) The evolution of insight, paranoia and depression during early schizophrenia. Psychological Medicine, 34, 285-292. (Pubitemid 38239636)
48. Lysaker PH, Buck KD, Salvatore G, Popolo R, Dimaggio G, (2009) Lack of awareness of illness in schizophrenia: conceptualizations, correlates and treatment approaches. Expert Review of Neurotherapeutics, 9, 1035-1043.
49. Saeedi H, Addington J, Addington D, (2007) The association of insight with psychotic symptoms, depression, and cognition in early psychosis: a 3-year follow-up. Schizophrenia Research, 89, 123-128. (Pubitemid 44881312)
50. Rocca P, Castagna F, Mongini T, Bogetto F, (2010) Relative contributions of psychotic symptoms and insight to quality of life in stable schizophrenia. Psychiatry Research, 177, 71-76.
51. Smith TE, Hull JW, Huppert JD, Silverstein SM, Anthony DT, McClough JF, (2004) Insight and recovery from psychosis in chronic schizophrenia and schizoaffective disorder patients. Journal of Psychiatric Research, 38, 169-176. (Pubitemid 38134458)
52. Addington D, Addington J, Maticka-Tyndale E, (1993) Assessing depression in schizophrenia: the Calgary Depression Scale. British Journal of Psychiatry Supplement, 22, 39-44. (Pubitemid 23355888)
53. Mohr P, (2007) Quality of life in the long-term treatment and the role of second-generation antipsychotics. Neuroendocrinology Letters, 28 (Suppl. 1), 117-133. (Pubitemid 46534377)
54. Möller HJ, (2005) Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? European Archives of Psychiatry and Clinical Neuroscience, 255, 190-201.
55. Kim JH, Ann JH, Kim MJ, (in press) Relationship between improvements of subjective well-being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychotics. Journal of Clinical Pharmacy and Therapeutics.
56. Mauri MC, Moliterno D, Rossattini M, Colasanti A, (2008) Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs. Schizophrenia Research, 99, 7-12. (Pubitemid 351249117)
57. McEvoy JP, Apperson LJ, Appelbaum PS, et al. (1989) Insight in schizophrenia. Its relationship to acute psychopathology. Journal of Nervous and Mental Disease, 177, 43-47. (Pubitemid 19043858)
58. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M, (1994) A self-report insight scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatrica Scandinavica, 89, 62-67. (Pubitemid 24028268)